The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2015 | The international Prognostic Index for patients with CLL (CLL-IPI)
Barbara Eichhorst
• 12 Jun 2015
At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, discusses a meta-analysis of 26 prognostic factors, including clinical, biological and genetic markers, in patients with chronic lymphocytic leukemia (CLL), for the development of an internationally applicable prognostic index, known as CLL-IPI.
